Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsPalmadottir, Vala Kolbrun
Andresdottir, Margret B
MetadataShow full item record
CitationPLoS ONE. 2010, 5(10):e13484
AbstractBACKGROUND: Oral sodium phosphate solutions (OSPS) are widely used for bowel cleansing prior to colonoscopy and other procedures. Cases of renal failure due to acute phosphate nephropathy following OSPS ingestion have been documented in recent years, questioning the safety of OSPS. However, the magnitude of the problem remains unknown. METHODOLOGY/PRINCIPAL FINDINGS: We conducted a population based, retrospective analysis of medical records and biopsies of all cases of acute phosphate nephropathy that were diagnosed in our country in the period from January 2005 to October 2008. Utilizing the complete official sales figures of OSPS, we calculated the incidence of acute phosphate nephropathy in our country. Fifteen cases of acute phosphate nephropathy were diagnosed per 17,651 sold doses of OSPS (0.085%). Nine (60%) were women and mean age 69 years (range 56-75 years). Thirteen patients had a history of hypertension (87%) all of whom were treated with either ACE-I or ARB and/or diuretics. One patient had underlying DM type I and an active colitis and one patient had no risk factor for the development of acute phosphate nephropathy. Average baseline creatinine was 81.7 µmol/L and 180.1 at the discovery of acute renal failure, mean 4.2 months after OSPS ingestion. No patient had a full recovery of renal function, and at the end of follow-up, 26.6 months after the OSPS ingestion, the average creatinine was 184.2 µmol/L. The average eGFR declined from 73.5 ml/min/1.73 m(2) at baseline to 37.3 ml/min/1.73 m(2) at the end of follow-up. One patient reached end-stage renal disease and one patient died with progressive renal failure. CONCLUSION/SIGNIFICANCE: Acute phosphate nephropathy developed in almost one out of thousand sold doses of OSPS. The consequences for kidney function were detrimental. This information can be used in other populations to estimate the impact of OSPS. Our data suggest that acute phosphate nephropathy may be greatly underreported worldwide.
DescriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links field
- Renal failure due to acute nephrocalcinosis following oral sodium phosphate bowel cleansing.
- Authors: Markowitz GS, Nasr SH, Klein P, Anderson H, Stack JI, Alterman L, Price B, Radhakrishnan J, D'Agati VD
- Issue date: 2004 Jun
- Acute phosphate nephropathy-an emerging threat.
- Authors: Ori Y, Herman M, Tobar A, Chernin G, Gafter U, Chagnac A, Izhak OB, Korzets A
- Issue date: 2008 Oct
- A prospective assessment of renal impairment after preparation for colonoscopy: oral sodium phosphate appears to be safe in well-hydrated subjects with normal renal status.
- Authors: Korsten MA, Spungen AM, Rosman AR, Ancha HR, Post JB, Shaw S, Hunt KK, Williams R 3rd, Bauman WA
- Issue date: 2010 Jul
- Acute phosphate nephropathy following oral sodium phosphate bowel purgative: an underrecognized cause of chronic renal failure.
- Authors: Markowitz GS, Stokes MB, Radhakrishnan J, D'Agati VD
- Issue date: 2005 Nov
- The effect of oral sodium phosphate drug products on renal function in adults undergoing bowel endoscopy.
- Authors: Khurana A, McLean L, Atkinson S, Foulks CJ
- Issue date: 2008 Mar 24